JP7491514B2 - 予防及び治療に有効な選択的抗がん剤 - Google Patents

予防及び治療に有効な選択的抗がん剤 Download PDF

Info

Publication number
JP7491514B2
JP7491514B2 JP2021502738A JP2021502738A JP7491514B2 JP 7491514 B2 JP7491514 B2 JP 7491514B2 JP 2021502738 A JP2021502738 A JP 2021502738A JP 2021502738 A JP2021502738 A JP 2021502738A JP 7491514 B2 JP7491514 B2 JP 7491514B2
Authority
JP
Japan
Prior art keywords
cancer
compound
acid
ethylflavopereirine
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021502738A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019191776A5 (https=
JP2021528480A5 (https=
JP2021528480A (ja
Inventor
ジョン， エル． ホール，
シルヴィー， ピー． ベリャンスキ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MOLECULAR INTERNATIONAL RESEARCH Inc
Original Assignee
MOLECULAR INTERNATIONAL RESEARCH Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MOLECULAR INTERNATIONAL RESEARCH Inc filed Critical MOLECULAR INTERNATIONAL RESEARCH Inc
Publication of JP2021528480A publication Critical patent/JP2021528480A/ja
Publication of JPWO2019191776A5 publication Critical patent/JPWO2019191776A5/ja
Publication of JP2021528480A5 publication Critical patent/JP2021528480A5/ja
Application granted granted Critical
Publication of JP7491514B2 publication Critical patent/JP7491514B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021502738A 2018-03-31 2019-04-01 予防及び治療に有効な選択的抗がん剤 Active JP7491514B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862651133P 2018-03-31 2018-03-31
US62/651,133 2018-03-31
PCT/US2019/025234 WO2019191776A1 (en) 2018-03-31 2019-04-01 Selective anti-cancer agent effective for prevention and treatment

Publications (4)

Publication Number Publication Date
JP2021528480A JP2021528480A (ja) 2021-10-21
JPWO2019191776A5 JPWO2019191776A5 (https=) 2022-04-06
JP2021528480A5 JP2021528480A5 (https=) 2022-04-06
JP7491514B2 true JP7491514B2 (ja) 2024-05-28

Family

ID=66175524

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021502738A Active JP7491514B2 (ja) 2018-03-31 2019-04-01 予防及び治療に有効な選択的抗がん剤

Country Status (5)

Country Link
US (1) US11083714B2 (https=)
EP (1) EP3773582B1 (https=)
JP (1) JP7491514B2 (https=)
CN (1) CN112601527B (https=)
WO (1) WO2019191776A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114224832A (zh) * 2022-02-11 2022-03-25 明度智云(浙江)科技有限公司 一种恩杂鲁胺注射剂及其制备方法和应用
WO2025068971A1 (en) * 2023-09-27 2025-04-03 Jina Pharmaceuticals Inc. Compositions containing cabazitaxel and lipids for oral administration
CN121466043A (zh) * 2026-01-09 2026-02-06 哈尔滨医科大学 香叶醇在制备胃癌化疗增敏剂中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415831A (en) 1965-07-16 1968-12-10 Smith Kline French Lab 2-isoquinolinyl(and carbolinyl) alkyloctahydroindolo [2,3-a]-quinolizines
US3468890A (en) 1966-06-09 1969-09-23 Sterling Drug Inc Pyrazino(1',2':1,2)pyrido(3,4-b)indoles
US3455936A (en) 1967-04-18 1969-07-15 Smithkline Corp Substituted indolo(2,3-a)quinolizinium salts
US3814773A (en) 1970-05-19 1974-06-04 American Home Prod Indole fused heterocyclic anti-inflammatory compounds
US3943148A (en) 1970-05-19 1976-03-09 American Home Products Corporation Indole fused heterocyclic diuretic compounds
HU169916B (https=) 1974-09-27 1977-02-28
FR2419725A1 (fr) 1978-03-13 1979-10-12 Beljanski Mirko Serpentine, alstonine et sempervirine, medicaments inhibant specifiquement les cellules cancereuses et tumorales
FR2450607A2 (fr) 1978-03-13 1980-10-03 Beljanski Mirko Composition pharmaceutique contenant comme principe actif la flavopereine
HU183234B (en) 1980-10-17 1984-04-28 Richter Gedeon Vegyeszet Process for the enantioselective synthesis of optically active cys-14-oxo-e-homo-eburnan
ATE15971T1 (de) 1981-03-11 1985-10-15 Mirko Beljanski Serpentin, alstonin und sempervirin, medikamente, die die tumor- und krebszellen spezifisch hemmen.
FR2639830B1 (fr) 1988-12-02 1991-03-22 Beljanski Mirko Composition antivirale et ses applications
FR2694693B1 (fr) 1992-07-28 1994-10-28 Abrax Bio Labs Sa Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH.
FR2751969B1 (fr) 1996-08-01 1998-12-04 Centre Nat Rech Scient Composes activateurs du canal cftr, et compositions pharmaceutiques les contenant
WO2002094270A2 (en) 2001-05-18 2002-11-28 Chemokine Therapeutics Corporation Mip-1 alpha receptor ligands - drugs for t-cell mediated and autoimmune diseases
EA008537B1 (ru) 2002-04-03 2007-06-29 Орион Корпорейшн Полициклические соединения как эффективные антагонисты альфа2-адренорецептора
JP4468638B2 (ja) 2003-01-31 2010-05-26 アリジェン製薬株式会社 インドール骨格を有するアルカロイドを含有するアスコフラノンの抗原虫作用増強剤およびこれらを含む抗原虫作用を有する薬剤組成物
JP4733058B2 (ja) 2004-02-18 2011-07-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ８−［３−アミノ−ピペリジン−１−イル］−キサンチン、その製造及びそのｄｐｐ−ｉｖインヒビターの形態での使用
US20090215853A1 (en) 2004-05-19 2009-08-27 Natural Source International Flavopereirine and alstonine combinations in the treatment and prevention of prostate cancer
US20100256177A1 (en) * 2004-06-11 2010-10-07 Seshagiri Venkatachalam Flavopereirine derivatives for cancer therapy
JP2012097060A (ja) 2010-11-01 2012-05-24 Tottori Univ 新規ジヒドロキシベンゼン誘導体およびそれらを有効成分とする抗原虫剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J.Org.Chem.，2016年，81(5)，pp.2194-2200
Org.Biomol.Chem.，2015年，13，pp.527-538
Org.Lett.，2014年，16，pp.3464-3467
Tetrahedron，1995年，Vol.51,No.3，pp.773-786

Also Published As

Publication number Publication date
EP3773582B1 (en) 2023-10-25
US11083714B2 (en) 2021-08-10
US20210015803A1 (en) 2021-01-21
EP3773582A1 (en) 2021-02-17
EP3773582C0 (en) 2023-10-25
CN112601527A (zh) 2021-04-02
CA3094388A1 (en) 2019-10-03
CN112601527B (zh) 2024-12-31
WO2019191776A1 (en) 2019-10-03
JP2021528480A (ja) 2021-10-21

Similar Documents

Publication Publication Date Title
Li et al. Disulfiram loaded calcium phosphate nanoparticles for enhanced cancer immunotherapy
JP7047148B2 (ja) 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
JP6837700B2 (ja) ジピベフリンの使用方法
JP2016512549A (ja) ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ
KR20150023752A (ko) 암 및 자가면역 질환 치료에 유용한 가역적인 공유 피롤로- 또는 피라졸로피리미딘
JP7491514B2 (ja) 予防及び治療に有効な選択的抗がん剤
CN111481551B (zh) 肿瘤选择性联合疗法
CA3012890A1 (en) Copanlisib biomarkers
CN106029070A (zh) 艾日布林和mTOR抑制剂作为治疗癌症的联合疗法的用途
Fong et al. Repurposing chloroquine analogs as an adjuvant cancer therapy
WO2024163751A1 (en) Formulations for treating cancer
Saxena et al. Targeting regulated cell death pathways in cancers for effective treatment: a comprehensive review
KR20200052326A (ko) 코판리십의 제제
US20240226104A1 (en) Pi3k inhibitors, nanoformulations, and uses thereof
US9173892B2 (en) Acadesine derivatives, products and compositions including same, therapeutic uses thereof, and methods for synthesizing same
CA3094388C (en) Use of de-ethylflavopereirine as a selective anti-cancer agent
KR102844084B1 (ko) 이브루티닙을 포함하는 제형/조성물
CN119894514A (zh) 药物组合物及其用途
US20260115190A1 (en) Dispersions of etrumadenant
US20240293430A1 (en) Withaferin a and immune checkpoint blocker combination therapies
Saxena¹ et al. Targeting regulated cell death pathways in cancers for effective
Piri-Gharaghie et al. dione (cyclo-Gly-L-DOPA or CG-Nio-CGLD) peptide loaded in Chitosan Glutamate-Coated Niosomes as anti-Colorectal cancer activity
AU2023341373A1 (en) Dispersions of etrumadenant
WO2026030527A1 (en) Formulations for treating cancer
TW202535398A (zh) 用於治療癌症之包含光學活性氮雜雙環衍生物之醫藥

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220329

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240416

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240507

R150 Certificate of patent or registration of utility model

Ref document number: 7491514

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150